Immune System

In people with amyotrophic lateral sclerosis (ALS), faster disease progression and decreased lifespan have been linked to immune system dysregulation and inflammatory processes. COYA302 is a subcutaneous injection drug therapy which has been shown to improve immune system regulation and suppress inflammation in people with ALS. This study will assess the safety, effects and long-term efficacy of COYA302 administered to patients with ALS.

The purpose of this study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major cardiovascular events when initiated as soon as possible in adult patients who have had a heart attack. Ziltivekimab is a medication designed to reduce inflammation after a heart attack, and thereby reduce secondary cardiac events.

The purpose of this study is to evaluate the safety, tolerability and preliminary activity of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with chronic graft-versus-host disease.

The purpose of this study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis who are 18 to 55 years of age at the time of enrollment. 

The purpose of this study is to collect biospecimens (fecal, urine, blood) and clinical data to serve as a resource for future research on Parkinson’s disease and other movement disorders. The careful collection, storage and retrieval of biospecimens and medical information for research projects are critical for improving understanding of healthy development and disease mechanisms and the subsequent development of effective treatments. Biospecimens from this biobank will be made available for ethically-approved studies.

The purpose of this study is to evaluate the immune response and safety of a new vaccine in preventing diseases due to infection with respiratory syncytial virus (RSV). This RSV vaccine will be tested in older adults who are recipients of lung or kidney transplants and are at an increased risk of RSV compared to healthy older adults. 

The purpose of this study is to assess the efficacy of two dose levels of brepocitinib in adults with dermatomyositis compared to a placebo. After 52 weeks of double-blind treatment, participants have the option to continue therapy in a 52-week, open-label extension phase where all participants will receive brepocitinib.

The purpose of this study is to characterize a recipient's immune system response to kidney transplantation to uncover an immune signature of early graft rejection.

The purpose of this study is to establish a protocol for improved human leukocyte antigen (HLA) matching for renal transplant patients.

The purpose of the study is to investigate the safety and efficacy of itolizumab versus placebo in individuals with acute graft-versus-host disease, when combined with corticosteroids as a first line treatment.